Homologous News and Research

RSS
Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Protective efficacy of BNT162b2 and Ad26.COV2.S against SARS-CoV-2 Omicron challenge in nonhuman primates

Effectiveness of COVID-19 vaccination 9 months post-vaccination for the population of Sweden

Effectiveness of COVID-19 vaccination 9 months post-vaccination for the population of Sweden

mRNA-based COVID-19 booster vaccination shown to protect against severe omicron infection in macaques

mRNA-based COVID-19 booster vaccination shown to protect against severe omicron infection in macaques

mRNA booster vaccination shown to induce robust neutralizing antibodies against SARS-CoV-2 omicron variant

mRNA booster vaccination shown to induce robust neutralizing antibodies against SARS-CoV-2 omicron variant

Predicting immunity evasion of SARS-CoV-2 Omicron variant of concern

Predicting immunity evasion of SARS-CoV-2 Omicron variant of concern

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Studying the efficacy of a SARS-CoV-2 vaccine booster dose

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Neutralizing antibodies against SARS-CoV-2 variants induced by homologous and heterologous COVID-19 booster vaccination

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Antigenic map of SARS-CoV-2 variants reveals amino acid substitutions that govern immune escape and immunodominance

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

Assessing the effects of booster vaccinations against SARS-CoV-2 Omicron variant

SARS-CoV-2 protein NSP2 found to impair microRNA-induced gene silencing in human cells

SARS-CoV-2 protein NSP2 found to impair microRNA-induced gene silencing in human cells

COVID-19 vaccines elicit cross-reactive antibodies against endemic coronaviruses

COVID-19 vaccines elicit cross-reactive antibodies against endemic coronaviruses

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

Homologous and heterologous COVID-19 booster vaccines found to be safe and immunogenic

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

SARS-CoV-2 virus co-opts intrinsic cellular machinery to suppress interferon production

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Immunogenicity to BNT162b2 booster in adults who had previously received inactivated COVID-19 vaccination

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Protection against SARS-CoV-2 Omicron afforded by Pfizer-BioNTech and Moderna boosters compared to two-dose primary series

Exploring the interactions between multiple respiratory viruses

Exploring the interactions between multiple respiratory viruses

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

Exploring SARS-CoV-2 Omicron variant’s neutralizing capacity of booster vaccines

Researchers construct models to predict SARS-CoV-2 mutable and constrained positions

Researchers construct models to predict SARS-CoV-2 mutable and constrained positions

Insignificant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens

Insignificant homology of SARS-CoV-2 spike sequences to myocarditis-associated antigens